The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
Abstract
Tumour necrosis factor alpha (TNF alpha) is a critical inflammatory mediator in rheumatoid arthritis, and may therefore be a useful target for specific immunotherapy. In support of this hypothesis, we previously observed beneficial responses in patients with active rheumatoid arthritis after open-label administration of a chimeric monoclonal antibody to TNF alpha (cA2). We now report the results of a four-centre, randomised double-blind trial of a single infusion of 1 or 10 mg/kg cA2 compared with placebo in 73 patients with active rheumatoid arthritis. The primary endpoint of the study was the achievement at week 4 of a Paulus 20% response, an amalgam of six clinical, observational, and laboratory variables. Intention-to-treat analysis of data from individual patients showed only 2 of 24 placebo recipients responding at this time, compared with 11 of 25 patients treated with low-dose cA2 (p = 0.0083) and 19 of 24 patients treated with high-dose cA2 (p < 0.0001). Over half of the high-dose cA2 patients responded by the more stringent 50% Paulus criteria at this time (p = 0.0005). The magnitude of these responses was impressive, with maximum mean improvements in individual disease-activity assessments, such as tender or swollen-joint counts and in serum C-reactive protein, exceeding 60% for patients on high-dose treatment. There were two severe adverse events. 1 patient on 1 mg/kg cA2 developed pneumonia ("possibly" treatment-related) and 1 on 10 mg/kg had a fracture ("probably not" treatment-related). The results provide the first good evidence that specific cytokine blockade can be effective in human inflammatory disease and define a new direction for the treatment of rheumatoid arthritis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent reports, for example, link germline genetic defects in type 1 IFN with exaggerated or severe COVID-19 response associated with neutrophilia 16,17 .”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [17]
In the citing paper
“TNF neutralization in the treatment of septic shock (13,14) and the use of IL-1 receptor antagonist (IL-1ra) and TNF antibody in the treatment of rheumatoid arthritis (15,16) suggest that these cytokines are important in the pathogenesis of the above disorders.”
From Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress (2007) · cites this paper as [15]
In the citing paper
“Clinical successes in the 1990s using drugs that specifically inhibit TNF for patients with inflammatory bowel disease or rheumatoid arthritis directly implicated a pathogenic role of this cytokine in other diseases (7-9) and validated in humans the fundamental premise of the cytokine theory of disease.”
From Physiology and immunology of the cholinergic antiinflammatory pathway (2007) · cites this paper as [7]
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITIS
STEINBROCKER, O. (1949) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1949.02900430001001 · Cited by 2,877
Pfeffer, K., Matsuyama, T., Kündig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P. S., Krönke, M., & Mak, T. W. (1993) · Cell · doi:10.1016/0092-8674(93)90134-c · Cited by 1,677
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., Furst, D., Goldsmith, C., Kieszak, S., Lightfoot, R., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,640
BRENNAN, F. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90430-3 · Cited by 1,129
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
Elliott, M. J., Maini, R. N., Feldmann, M., Long‐Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361206 · Cited by 1,038
Self-citationAnti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Williams, R. O., Feldmann, M., & Maini, R. N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9784 · Cited by 989
Self-citationConstruction and initial characterization of a mouse-human chimeric anti-TNF antibody
Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, M. A., Vilcek, J., Daddona, P., et al. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90106-l · Cited by 703
Elliott, M. J., Maini, R. N., Feldmann, M., Long-Fox, A., Charles, P., Bijl, J. A., & Woody, J. N. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90632-7 · Cited by 640
Self-citationEvidence that tumor necrosis factor has an important role in antibacterial resistance.
Havell, E. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.9.2894 · Cited by 405
Research works printed but not linked: 3
- Moreland, 1993, Double blind placebo-controlled phase II trial of diphtheria-interleukin-2 fusion toxin (DAB486IL-2) in patients with refractory rheumatoid arthritis (RA), Arthritis Rheum, 36, S39
- Moreland, 1993, Minimal efficacy of a depleting chimaeric anti-CD4 (cM-T412) in treatment of patients with refractory rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX), Arthritis Rheum, 36, S39
- Pa van der Lubbe, Ba Dijkmans, Hm Markusse, et al., Lack of clinical effect of CD4 monoclonal antibody therapy in early rheumatoid arthritis: a placebo controlled trial, Arthritis Rheum ((in press)).
Cited by
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
Barnes, P. J., & Karin, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361506 · Cited by 4,669
Evolving concepts of rheumatoid arthritis
Firestein, G. S. (2003) · Nature · doi:10.1038/nature01661 · Cited by 3,605
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationSmolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., Kavanaugh, A., McInnes, I. B., Solomon, D. H., Strand, V., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.1 · Cited by 2,445
Self-citation
Metadata
- Authors
- Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., & Woody, J. N.
- Affiliations
- Hammersmith Hospital (GB)
- Universitätsklinikum Erlangen (DE)
- University of Pennsylvania Press (US)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1994-10
- Volume
- 344
- Issue
- 8930
- Pages
- 1105-1110
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2142273705
- Cited by
- 1,682
- References
- 24
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 20 · 2023: 14 · 2022: 23 · 2021: 18 · 2020: 22 · 2019: 23 · 2018: 23 · 2017: 21 · 2016: 22 · 2015: 43 · 2014: 34 · 2013: 39 · 2012: 31
- FWCI
- 63.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, chimeric monoclonal antibody, CA2, TNF-α, TNF-alpha blockade, cytokine inhibition, disease activity, C-reactive protein, adverse events, pneumonia, fracture
- MeSH terms
- Infliximab, Adolescent, Adult, Aged, Antibodies, Monoclonal, Arthritis, Rheumatoid, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Pain Measurement, Placebos, Tumor Necrosis Factor-alpha, Antirheumatic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. https://app.cochat.ai/papers/10.1016/s0140-6736(94)90628-9
- The paper
- Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., & Woody, J. N. (1994). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. The Lancet. https://doi.org/10.1016/s0140-6736(94)90628-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.